by Corey S. Cutler, John Koreth, and Jerome Ritz

Slides:

Advertisements

Similar presentations

Blockade of osteopontin reduces alloreactive CD8 + T cell– mediated graft-versus-host disease by Fang Zhao, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang.

Advertisements

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD by Ana C. Alho, Haesook T.

Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Uncontrolled Wnt signaling causes leukemia

The beauty of TLR agonists for CTCL

GVHD-associated immunodeficiency: soil or seed?

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

MBL: mostly benign lymphocytes, but…

TCR-MHC-peptide(s): in vivo veritas

Next-generation leukemia immunotherapy

When monocyte life hangs by a thread

It's all in the timing by Linda J. Bendall Blood

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

BRAF inhibitor: targeted therapy in hairy cell leukemia

T regulatory cells turn on T regulatory cells

Gnawing at Metchnikoff’s paradigm

Genetic sequence analysis of inherited bleeding diseases

Functional neutrophils from human ES cells

Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans.

Basophils take a slice of IRF8 pie

Rare cells predict GVHD

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.

Biology of Blood and Marrow Transplantation

Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.

Has MRD monitoring superseded other prognostic factors in adult ALL?

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

HU for acute treatment of sickle VOC?

Anergy: the CLL cell limbo

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

B Cells in Chronic Graft-versus-Host Disease

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Chronic graft-versus-host disease

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Mitchell S. Cairo, Willi Woessmann, John Pagel

Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow Transplant

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical.

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

by Christine L. Kempton, and Amanda B. Payne

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Proposed model of molecular pathogenesis in the development and progression of major subtypes of MCL. Precursor B cells usually with but sometimes without.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Sarah Nikiforow, Haesook T

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

by Lapo Alinari, and Kristie A. Blum

A, Natalizumab blocks the adhesion of leukocytes to endothelial cells by blocking the interaction of the α4-integrin subunit of α4β1 with VCAM-1 and of.

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Normal pathway of B12 absorption and cellular uptake.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone.

by Jennifer N. Brudno, and James N. Kochenderfer

Presentation transcript:

by Corey S. Cutler, John Koreth, and Jerome Ritz Mechanistic approaches for the prevention and treatment of chronic GVHD by Corey S. Cutler, John Koreth, and Jerome Ritz Blood Volume 129(1):22-29 January 5, 2017 ©2017 by American Society of Hematology

Mechanistic interventions for the prevention or treatment of chronic GVHD. Current and new approaches for the prevention or treatment of chronic GVHD primarily target alloreactive donor T cells, allo- and autoreactive B cells, or CD4+FoxP3+ regulatory T cel... Mechanistic interventions for the prevention or treatment of chronic GVHD. Current and new approaches for the prevention or treatment of chronic GVHD primarily target alloreactive donor T cells, allo- and autoreactive B cells, or CD4+FoxP3+ regulatory T cells. As advances in our understanding of the role of each of these cell types in the development of chronic GVHD has advanced in recent years, it is now possible to develop and select for clinical testing a variety of therapeutic interventions that focus on specific mechanistic pathways. Professional illustration by Patrick Lane, ScEYEnce Studios. Corey S. Cutler et al. Blood 2017;129:22-29 ©2017 by American Society of Hematology